5 SIMPLE STATEMENTS ABOUT ABBV-744 CLINICAL TRIAL PHASE 1 RESULTS EXPLAINED

In Segment A, participants will acquire unique doses and schedules of oral ABBV-744 tablet to identify safe dosing program. Added individuals will probably be enrolled in the determined monotherapy dosign regimen. In Section B, participants will acquire oral ruxolitinib and ABBV-744 might be presented as "include-on" therapy. In Phase C, individual